In the field of Oncology, Genetic testing is needed in many aspects such as early diagnosis, targeted drug use, efficacy monitoring, and monitoring of micro residues, to provide a more reliable and objective basis for clinical decision making in oncology.

Take lung cancer patients as an example, there are only a few genes that need to be tested most: EGFR, ALK, ROS1, KRAS and so on. These genes are all commonly mutated in lung cancer and can clearly guide the use of targeted drugs.

There are three ways to obtain samples in clinical practice: 1. Tumor samples obtained during surgery; 2. Puncture biopsy samples; 3. "liquid biopsy". The surgical tissue sample is the most accurate, the puncture biopsy is less invasive, and the "liquid biopsy" has the advantage of being non-invasive and repeatable.

Tumor samples are often obtained from small amounts of material, especially puncture biopsies, and the number of tumor nucleic acids in liquid biopsies is even smaller. Therefore, tumor genetic testing requires high sensitivity for nucleic acid detection technology.

Digital PCR has the advantage of high sensitivity, which is exactly for oncogene detection. It promises to be one of the most accurate and reliable tools for tumor diagnosis, treatment and monitoring.